Intellia Therapeutics, Inc. (Nasdaq: NTLA) has shared updated interim results from the Phase 1 portion of their ongoing study of NTLA-2002, a CRISPR candidate for treating hereditary angioedema (HAE). 

The company believes that the data reinforces the potential of NTLA-2002 to serve as a functional cure for individuals with HAE. Patients who received a single dose of the therapy experienced long-lasting relief from attacks, with some remaining attack-free for over a year. The safety profile of NTLA-2002 was also found to be highly favorable.

Intellia's President and CEO, Dr. John Leonard, expressed enthusiasm about the consistent reduction in attack rates, even in patients with severe symptoms. 

On Friday, $NTLA closed at $43.24, showing a slight decrease of $0.12 (-0.28%).

Ocular Therapeutix, Inc. (Nasdaq: OCUL) has released 12-month data from its Phase 1 clinical trial testing the Company’s axitinib intravitreal hydrogel implant OTX-TKI to treat wet age-related macular degeneration (wet AMD).

The data showed that OTX-TKI maintained controlled wet AMD subjects comparable to aflibercept injections every eight weeks, with a significant reduction in treatment burden by 89% over the 12-month period. 

No serious drug-related adverse events were observed, and the implant bioresorbed consistently at around eight to nine months, informing potential redosing timeline. 

$OCUL closed at $7.43 on Friday, down $0.18 (-2.37%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)